President Trump announced an additional round of voluntary pricing agreements with drugmakers, bringing nine new companies into a broader set of arrangements that previously included 17 manufacturers. The administration frames these deals as part of an ongoing effort to lower U.S. drug prices through voluntary commitments by biopharma companies.
The nine companies named in the announcement are Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB. All of the new participants except BridgeBio are headquartered outside the United States.
According to the announcement, the companies agreed to several types of pledges. Those include selling new medicines to U.S. patients at prices comparable to the lowest prices available in peer countries and offering their drugs to state Medicaid programs at most-favored nation prices. In some instances, companies also pledged to increase domestic manufacturing capacity or to contribute supplies to U.S. medical stockpiles. The White House indicated that, in return for these commitments, at least some companies may avoid tariffs.
Four companies — UCB, Sun Pharma, Teva, and Astellas — committed a combined total of 290 metric tons of active pharmaceutical ingredients to the nation’s strategic reserves. Beyond that contribution, the announcement referenced commitments to bolster domestic manufacturing from some participants, though specific manufacturing details were not provided in the public account.
The administration has not released the full text or detailed terms of the new agreements. The report states that the details of the deals, including how they would affect Medicare pricing or coverage, remain undisclosed. Because the agreements are described as voluntary and private, the mechanics of implementation and enforcement were not described in the available report.
Observers and analysts noted uncertainty about how much these voluntary deals will change drug costs or improve access. Medicaid already receives the lowest drug prices among U.S. payers, and two of the companies making new deals, Teva and Sun Pharma, are known for their roles in generic medicines. Those factors complicate assessments of the deals’ potential to lower prices broadly across payers and patient populations.
The announcement comes after months in which biotech and pharmaceutical companies approached the administration to seek agreement terms that might avoid what they view as price controls tied to federal initiatives. The report notes that the voluntary deals do not indicate full industry alignment with the administration’s broader objectives: company leaders have been reluctant to publicly back the administration’s drug pricing legislation, and some companies are considering legal challenges to federal pricing policies they oppose.
The White House has pushed Congress to codify elements of the approach, while keeping the agreements’ terms largely private.
Health Secretary Robert F. Kennedy Jr. said the deals now cover nine out of 10 drugs prescribed in the United States, according to the report. The announcement was presented as part of a broader administration campaign that includes the TrumpRx drug purchasing platform. The report notes that TrumpRx has not achieved all of its stated goals and that the administration has highlighted declines in certain drug prices, even as independent details and evaluations of the deals remain limited.
The new agreements represent an expansion of the administration’s drug pricing agenda and follow earlier statements that officials planned to negotiate with many more manufacturers. The arrangements described are temporary, voluntary commitments tied to the current administration’s term, and the long-term impact on drug pricing, Medicare, and market behavior remains unclear in the absence of more complete public documentation.